Camber Pharmaceuticals Launches Generic Stendra®
Piscataway, NJ, October 29, 2024 – Camber Pharmaceuticals is excited to expand its product line with Avanafil Tablets. A study by the Cleveland Clinic reveals that about 40% of men experience erectile dysfunction (ED) by age 40, with this number rising to nearly 70% by age 70.
Avanafil Tablets is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.
Avanafil Tablets are available in 50, 100 and 200 mg strengths in 30 count bottles.
To learn more about Avanafil Tablets, please visit www.camberpharma.com/avanafil
Recent articles
- Camber Specialty Marks First Day 1 Injectable Launch
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
- Camber Welcomes Summer 2026 Intern Class






